



Request for Public Comment - Nalmefene Nasal Spray (Comments Due 7.28.23)

Ohio law defines an overdose reversal drug as both of the following:

(1) Naloxone;

(2) Any other drug that the state board of pharmacy, through rules adopted in accordance with Chapter 119. of the Revised Code, designates as a drug that is approved by the Federal Food and Drug Administration for the reversal of a known or suspected opioid-related overdose.

On May 22, 2023, the [FDA approved](#) nalmefene hydrochloride nasal spray ([Opvee](#)) for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.

The Board is requesting public comment on the possibility of adding nalmefene hydrochloride nasal spray under the definition of an overdose reversal drug. By doing so, nalmefene hydrochloride nasal spray would be available for widespread lay distribution in Ohio without a prescription, like naloxone (see [guidance here](#)).

More information on Opvee can be found here:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf

To submit comments for the Board's review, please complete the online comment form by visiting: <https://www.surveymonkey.com/r/nalmefene>

Please note that if you choose to unsubscribe from receiving emails, this unsubscribes you from all emails that are sent by the State of Ohio Board of Pharmacy, including renewal reminders. If you believe you have unsubscribed in error, you may subscribe by visiting: www.pharmacy.ohio.gov/subscribe. If you would like to change the email address, please log into your [eLicense Ohio](#) account to update the email address on file.